Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.

Chao BH, Lepeak L, Leal T, Robins HI.

Thrombosis. 2011;2011:530183. doi: 10.1155/2011/530183. Epub 2011 Apr 12.

2.

Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.

Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P.

Cochrane Database Syst Rev. 2014 Feb 11;(2):CD001689. doi: 10.1002/14651858.CD001689.pub3. Review.

PMID:
24519568
3.

The heparins and cancer: review of clinical trials and biological properties.

Castelli R, Porro F, Tarsia P.

Vasc Med. 2004 May;9(3):205-13. Review.

PMID:
15675186
4.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR.

J Thromb Haemost. 2013 Jan;11(1):56-70. doi: 10.1111/jth.12070. Review.

6.

Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.

Mousa SA, Petersen LJ.

Thromb Haemost. 2009 Aug;102(2):258-67. doi: 10.1160/TH08-12-0832. Review.

PMID:
19652876
7.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Di Nisio M, Porreca E, Otten HM, Rutjes AW.

Cochrane Database Syst Rev. 2014 Aug 29;(8):CD008500. doi: 10.1002/14651858.CD008500.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 01;12 :CD008500.

8.

Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

van Der Heijden JF, Hutten BA, Büller HR, Prins MH.

Cochrane Database Syst Rev. 2000;(4):CD002001. Review. Update in: Cochrane Database Syst Rev. 2002;(1):CD002001.

PMID:
11034739
9.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008500. doi: 10.1002/14651858.CD008500.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(8):CD008500.

10.

[Treatment of venous thromboembolic disease in cancer patients].

Farge-Bancel D, Florea L, Bosquet L, Debourdeau P.

Pathol Biol (Paris). 2008 Jun;56(4):220-8. doi: 10.1016/j.patbio.2008.02.007. Epub 2008 Apr 3. Review. French.

PMID:
18394821
11.

Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.

Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM.

Pharmacotherapy. 2012 Sep;32(9):799-808. doi: 10.1002/j.1875-9114.2012.01106.x. Epub 2012 Jun 28. Review.

PMID:
22744711
12.

Clinical use of parnaparin in major and minor orthopedic surgery: a review.

Bugamelli S, Zangheri E, Montebugnoli M, Guerra L.

Vasc Health Risk Manag. 2008;4(5):983-90. Review.

13.

Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.

Tapson VF, Hull RD.

Clin Chest Med. 1995 Jun;16(2):281-94. Review.

PMID:
7656540
14.

Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.

Pineo GF, Hull RD.

Clin Appl Thromb Hemost. 2009 Oct;15(5):489-500. doi: 10.1177/1076029609335910. Epub 2009 Jun 10. Review.

PMID:
19520676
15.

Low molecular weight heparins in the treatment of lung cancer.

Mellema WW, Smit EF, Dingemans AM.

Expert Opin Investig Drugs. 2011 Nov;20(11):1517-22. doi: 10.1517/13543784.2011.625008. Epub 2011 Oct 7. Review.

PMID:
21978327
16.

VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.

Cohen AT, Nandini B, Wills JO, Ota S.

Thromb Res. 2010 Apr;125 Suppl 2:S21-9. doi: 10.1016/S0049-3848(10)70008-6. Review.

PMID:
20434000
17.

Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.

Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, Martí-Mestre X, Colomé E, Iguaz I.

Ann Vasc Surg. 2010 Jul;24(5):628-39. doi: 10.1016/j.avsg.2009.08.006. Epub 2009 Nov 25. Review.

PMID:
19932949
18.

Safety of anticoagulant treatment in cancer patients.

Wilts IT, Bleker SM, Van Es N, Büller HR, Di Nisio M, Kamphuisen PW.

Expert Opin Drug Saf. 2015 Aug;14(8):1227-36. doi: 10.1517/14740338.2015.1052739. Epub 2015 Jun 10. Review.

PMID:
26059964
19.

[Cancer-associated venous thromboembolic recurrence: disregard of treatment recommendations].

Mahé I, Chidiac J.

Bull Cancer. 2014 Mar;101(3):295-301. doi: 10.1684/bdc.2014.1907. Review. French.

PMID:
24691192
20.

The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis.

Cunningham RS.

Semin Oncol. 2006 Apr;33(2 Suppl 4):S17-25; quiz S41-2. Review.

PMID:
16638457

Supplemental Content

Support Center